On June 3, 2009, Pfizer Animal Health announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S. – PALLADIA™ (toceranib phosphate) – which was developed by Pfizer to treat mast cell tumors in dogs. Pfizer made the announcement to veterinarians attending the 2009 American College of Veterinary Internal Medicine (ACVIM) Forum and Canadian Veterinary Medical Association Convention. "Pfizer Animal Health is proud to bring the first canine cancer therapy approved by the FDA to U.S. specialists, their patients and caregivers," said George Fennell, vice president, Companion Animal Division, Pfizer Animal Health. "In the weeks and months ahead, Pfizer will introduce PALLADIA; to boarded specialists to expand the body of clinical experience with this new therapy. The experience gained during this time will enable us to support veterinarians more effectively when we make the product available for purchase in early 2010," Fennell said.